| David Brian Parmet, MD | |
|
4401 Wornall Rd, Kansas City, MO 64111-3220 | |
| (816) 932-0340 | |
| (816) 932-3148 |
| Full Name | David Brian Parmet |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 23 Years |
| Location | 4401 Wornall Rd, Kansas City, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174537997 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Luke's South Hospital | Overland park, KS | Hospital |
| St Lukes Hospital Of Kansas City | Kansas city, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Saint Lukes Physician Group Inc | 3577476894 | 1070 |
| Saint Lukes Physician Group Inc | 3577476894 | 1070 |
News Archive
A computer vision technology developed by University of Cambridge engineers has now been developed into a free mobile phone app for regular monitoring of glucose levels in people with diabetes.
When pregnant women need medications, there is often concern about possible effects on the fetus. Although some drugs are clearly recognized to cause birth defects, and others are generally recognized as safe, surprisingly little is known about most drugs' level of risk. Researchers in the Children's Hospital Boston Informatics Program have created a preclinical model for predicting a drug's teratogenicity based on characterizing the genes that it targets.
VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.
The new target, a molecule called hVps34, is activated by amino acids (nutrients) entering the cell. This molecule triggers the activation of an enzyme, S6 Kinase 1 (S6K1), whose function UC researchers linked last year to obesity and insulin resistance.
› Verified 2 days ago
| Entity Name | Saint Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093263717 PECOS PAC ID: 3577476894 Enrollment ID: O20031111000818 |
News Archive
A computer vision technology developed by University of Cambridge engineers has now been developed into a free mobile phone app for regular monitoring of glucose levels in people with diabetes.
When pregnant women need medications, there is often concern about possible effects on the fetus. Although some drugs are clearly recognized to cause birth defects, and others are generally recognized as safe, surprisingly little is known about most drugs' level of risk. Researchers in the Children's Hospital Boston Informatics Program have created a preclinical model for predicting a drug's teratogenicity based on characterizing the genes that it targets.
VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.
The new target, a molecule called hVps34, is activated by amino acids (nutrients) entering the cell. This molecule triggers the activation of an enzyme, S6 Kinase 1 (S6K1), whose function UC researchers linked last year to obesity and insulin resistance.
› Verified 2 days ago
| Entity Name | Saint Lukes Hospital Of Chillicothe |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245433127 PECOS PAC ID: 0143130393 Enrollment ID: O20041014000548 |
News Archive
A computer vision technology developed by University of Cambridge engineers has now been developed into a free mobile phone app for regular monitoring of glucose levels in people with diabetes.
When pregnant women need medications, there is often concern about possible effects on the fetus. Although some drugs are clearly recognized to cause birth defects, and others are generally recognized as safe, surprisingly little is known about most drugs' level of risk. Researchers in the Children's Hospital Boston Informatics Program have created a preclinical model for predicting a drug's teratogenicity based on characterizing the genes that it targets.
VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.
The new target, a molecule called hVps34, is activated by amino acids (nutrients) entering the cell. This molecule triggers the activation of an enzyme, S6 Kinase 1 (S6K1), whose function UC researchers linked last year to obesity and insulin resistance.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Brian Parmet, MD 901 E 104th St, Kansas City, MO 64131-4517 Ph: (816) 502-8752 | David Brian Parmet, MD 4401 Wornall Rd, Kansas City, MO 64111-3220 Ph: (816) 932-0340 |
News Archive
A computer vision technology developed by University of Cambridge engineers has now been developed into a free mobile phone app for regular monitoring of glucose levels in people with diabetes.
When pregnant women need medications, there is often concern about possible effects on the fetus. Although some drugs are clearly recognized to cause birth defects, and others are generally recognized as safe, surprisingly little is known about most drugs' level of risk. Researchers in the Children's Hospital Boston Informatics Program have created a preclinical model for predicting a drug's teratogenicity based on characterizing the genes that it targets.
VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.
The new target, a molecule called hVps34, is activated by amino acids (nutrients) entering the cell. This molecule triggers the activation of an enzyme, S6 Kinase 1 (S6K1), whose function UC researchers linked last year to obesity and insulin resistance.
› Verified 2 days ago
Subashis Paul, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 2301 Main St, Kansas City, MO 64108 Phone: 816-395-3558 | |
Tyler Porter, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 | |
Christine M. Sankpill, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
Anuhya Caipa Young, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
David A Wooldridge, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
Peter Lebourveau, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
David C Hermanns, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2301 Holmes St, Kansas City, MO 64108 Phone: 816-404-1000 |